午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

返回ChemicalBook首頁(yè)>CAS數(shù)據(jù)庫(kù)列表>223132-38-5

223132-38-5

中文名稱 5-[[4-[[6-(4-氨基-3,5-二甲基苯氧基)-1-甲基-1H-苯并咪唑-2-基]甲氧基]苯基]甲基]-2,4-噻唑烷二酮二鹽酸鹽
英文名稱 CS 7017
CAS 223132-38-5
分子式 C27H28Cl2N4O4S
分子量 575.507
MOL 文件 223132-38-5.mol
更新日期 2024/11/15 18:20:32
223132-38-5 結(jié)構(gòu)式 223132-38-5 結(jié)構(gòu)式

基本信息

中文別名
PPARΓ激動(dòng)劑(INOLITAZONE DIHYDROCHLORIDE)
5-[[4-[[6-(4-氨基-3,5-二甲基苯氧基)-1-甲基-1H-苯并咪唑-2-基]甲氧基]苯基]甲基]-2,4-噻唑烷二酮二鹽酸鹽
英文別名
CS 7017
RS5444 dihydrochloride
CS-7017 dihydrochloride
Inolitazone (CS-7017) 2HCl
Efatutazone dihydrochloride
Inolitazone (dihydrochloride)
Inolitazone (CS-7017) dihydrochloride
EFATUTAZONE
CS-7017
RS5444
CS 7017
RS 5444
5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methylbenzimidazol-2-yl]methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[[6-(4-Amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-thiazolidinedione dihydrochloride
所屬類別
生物化工:激動(dòng)劑抑制劑

物理化學(xué)性質(zhì)

儲(chǔ)存條件-20°C儲(chǔ)存
溶解度DMSO : 25 mg/mL (43.44 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble)
形態(tài)粉末
顏色Pale purple to purple

常見問題列表

生物活性
Inolitazone dihydrochloride (Efatutazone dihydrochloride) 是一種高親和力的 PPARγ 激動(dòng)劑,活性依賴于 PPARγ,抑制生長(zhǎng),IC50 為 0.8 nM。
靶點(diǎn)

PPARγ

體外研究

Inolitazone dihydrochloride (Efatutazone dihydrochloride) upregulates the cell cycle kinase inhibitor, p21 WAF1/CIP1 . Silencing p21 WAF1/CIP1 rendered cells insensitive to Inolitazone. A 10 nM dose of Inolitazone activates PPARγ:RXRα-dependent transcription as demonstrated in a transient transfection assay utilizing a PPRE response element fused to a luciferase reporter gene (PPRE3-tk-luc). DRO cells are treated in culture with Inolitazone, Rosiglitazone, or Troglitazone at the indicated concentrations. DRO cells are transiently transfected with PPRE3-tk-luc to examine effective concentrations at which EC 50 occurs. The EC 50 s are 1 nM (Inolitazone), 65 nM (Rosiglitazone) and 631 nM (Troglitazone). Similarly, the calculated inhibitory concentration at IC 50 is 0.8 nM for Inolitazone, 75 nM for Rosiglitazone, and 1412 nM for Troglitazone. Inolitazone specifically activates PPARγ, but not PPARα or PPARδ. Exposure of 10 nM Inolitazone following transient transfection with the appropriate PPAR isoform (γ, α, or δ) and PPAR response element linked to a luciferase reporter in RIE rat small intestinal cell line, which does not express PPARs, yields increased luciferase activity only in the presence of PPARγ and PPRE3-tk-luc.
DRO cells are growth inhibited by 10 nM Inolitazone (RS5444) through a PPARγ-dependent mechanism.

體內(nèi)研究

Inolitazone dihydrochloride (Efatutazone dihydrochloride) plus Paclitaxel demonstrate additive antiproliferative activity in cell culture and minimal ATC tumor growth. When Inolitazone is administered in the diet to athymic nude mice prior to DRO tumor cell implantation, tumor growth is inhibited in a dose responsive fashion. At the highest dose, 0.025% Inolitazone inhibits growth on day 32 by 94.4% as compared to that of control. In this treatment group, five of 10 animals do not develop demonstrable tumors. In the 0.0025% treatment group, tumor growth is inhibited by 62.3% compared to that of control on day 32 while the 0.00025% dose demonstrated no growth inhibitory activity as compared to control. Tumors is nest allowed to establish in the mouse and began 0.025% Inolitazone treatment of mice 1 week after DRO or ARO tumor cell implantation. Inolitazone treated animals demonstrate tumor growth inhibition of 68.9% in DRO tumors and 48.3% in ARO tumors as compared to that of their respective controls on day 35.

"223132-38-5" 相關(guān)產(chǎn)品信息
55406-53-6 100-44-7 87-62-7 121-69-7 106-42-3